皮膚T細胞リンパ腫(Cutaneous T-Cell Lymphoma)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Cutaneous T-Cell Lymphoma – Overview 10
Pipeline Products for Cutaneous T-Cell Lymphoma – Comparative Analysis 11
Cutaneous T-Cell Lymphoma – Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma – Therapeutics under Investigation by Universities/Institutes 14
Cutaneous T-Cell Lymphoma – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cutaneous T-Cell Lymphoma – Products under Development by Companies 18
Cutaneous T-Cell Lymphoma – Products under Investigation by Universities/Institutes 20
Cutaneous T-Cell Lymphoma – Companies Involved in Therapeutics Development 21
Affimed Therapeutics AG 21
Chipscreen Biosciences Ltd 22
Cornerstone Pharmaceuticals, Inc. 23
Cyclacel Pharmaceuticals, Inc. 24
Eisai Co., Ltd. 25
Galderma S.A. 26
Innate Pharma SA 27
Johnson & Johnson 28
Karyopharm Therapeutics, Inc. 29
Kyowa Hakko Kirin Co., Ltd. 30
MedImmune, LLC 31
Neumedicines Inc. 32
Novartis AG 33
OncoSec Medical Inc. 34
Onyx Pharmaceuticals, Inc. 35
Sanofi 36
Soligenix, Inc. 37
Taiwan Liposome Company, Ltd. 38
Takeda Pharmaceutical Company Limited 39
TetraLogic Pharmaceuticals 40
Cutaneous T-Cell Lymphoma – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
A-dmDT390-bisFv – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AFM-13 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alemtuzumab – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AMP-224 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Angeloxin – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
bexarotene – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
brentuximab vedotin – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
carfilzomib – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CIGB-128 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CPI-613 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CS-055 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
DNA IL-12 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
everolimus – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
IPH-4102 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
mogamulizumab – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NMIL-121 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
quisinostat – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
sapacitabine – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
selinexor – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SGX-301 – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SHP-141 – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
trifarotene – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
vinorelbine tartrate – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Cutaneous T-Cell Lymphoma – Recent Pipeline Updates 102
Cutaneous T-Cell Lymphoma – Dormant Projects 164
Cutaneous T-Cell Lymphoma – Discontinued Products 167
Cutaneous T-Cell Lymphoma – Product Development Milestones 168
Featured News & Press Releases 168
Jan 07, 2015: FDA Grants Soligenix Fast Track”Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma 168
Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 168
Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research 169
Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 169
Aug 27, 2014: Innate Pharma’s IPH4102 Receives Orphan Drug Designation In European Union 170
Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries 170
Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 171
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 172
Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 173
Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 173
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175